UY34496A - Formulacion nasal - Google Patents
Formulacion nasalInfo
- Publication number
- UY34496A UY34496A UY0001034496A UY34496A UY34496A UY 34496 A UY34496 A UY 34496A UY 0001034496 A UY0001034496 A UY 0001034496A UY 34496 A UY34496 A UY 34496A UY 34496 A UY34496 A UY 34496A
- Authority
- UY
- Uruguay
- Prior art keywords
- nasal formulation
- formulation
- nasal
- azelastine
- cosolvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención se relaciona con una formulación de solución para la administración nasal que comprende azelastina, dipropionato de beclometasona, un cosolvente, un ácido y un propelente de HFA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161567893P | 2011-12-07 | 2011-12-07 | |
GBGB1121812.0A GB201121812D0 (en) | 2011-12-07 | 2011-12-19 | NAsal formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34496A true UY34496A (es) | 2014-05-30 |
Family
ID=48693842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034496A UY34496A (es) | 2011-12-07 | 2012-12-06 | Formulacion nasal |
Country Status (15)
Country | Link |
---|---|
US (1) | US20130167838A1 (es) |
EP (1) | EP2788001B1 (es) |
AR (1) | AR089101A1 (es) |
CA (1) | CA2856043C (es) |
DK (1) | DK2788001T3 (es) |
ES (1) | ES2560029T3 (es) |
GB (1) | GB201121812D0 (es) |
HK (1) | HK1200342A1 (es) |
HU (1) | HUE026612T2 (es) |
IL (1) | IL232944A0 (es) |
MX (1) | MX2014006769A (es) |
PL (1) | PL2788001T3 (es) |
TW (1) | TWI468193B (es) |
UY (1) | UY34496A (es) |
WO (1) | WO2013083569A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2906008C (en) | 2013-03-13 | 2019-07-09 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
GB201408229D0 (en) | 2014-05-09 | 2014-06-25 | Norton Waterford Ltd | Aerosol device |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9805938D0 (en) | 1998-03-19 | 1998-05-13 | Glaxo Group Ltd | Valve for aerosol container |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
TW200522932A (en) | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
JP2008534509A (ja) * | 2005-03-23 | 2008-08-28 | エラン ファーマ インターナショナル リミテッド | ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤 |
CA2661129A1 (en) * | 2006-08-22 | 2008-02-28 | Glaxo Group Limited | Actuator for an inhaler |
GB0719257D0 (en) * | 2007-10-04 | 2007-11-14 | 3M Innovative Properties Co | Metered dose dispenser |
GB0721739D0 (en) * | 2007-11-06 | 2007-12-19 | 3M Innovative Properties Co | medicinal inhalation devices and components thereof |
ES2712996T3 (es) * | 2010-10-12 | 2019-05-17 | Ivax Pharmaceuticals Ireland | Dispositivo de pulverización nasal |
-
2011
- 2011-12-19 GB GBGB1121812.0A patent/GB201121812D0/en not_active Ceased
-
2012
- 2012-12-04 DK DK12797884.9T patent/DK2788001T3/en active
- 2012-12-04 EP EP12797884.9A patent/EP2788001B1/en not_active Not-in-force
- 2012-12-04 ES ES12797884.9T patent/ES2560029T3/es active Active
- 2012-12-04 MX MX2014006769A patent/MX2014006769A/es unknown
- 2012-12-04 CA CA2856043A patent/CA2856043C/en not_active Expired - Fee Related
- 2012-12-04 HU HUE12797884A patent/HUE026612T2/hu unknown
- 2012-12-04 PL PL12797884T patent/PL2788001T3/pl unknown
- 2012-12-04 WO PCT/EP2012/074374 patent/WO2013083569A1/en active Application Filing
- 2012-12-06 UY UY0001034496A patent/UY34496A/es not_active Application Discontinuation
- 2012-12-06 AR ARP120104578A patent/AR089101A1/es not_active Application Discontinuation
- 2012-12-07 TW TW101146277A patent/TWI468193B/zh not_active IP Right Cessation
- 2012-12-07 US US13/708,314 patent/US20130167838A1/en not_active Abandoned
-
2014
- 2014-06-02 IL IL232944A patent/IL232944A0/en unknown
-
2015
- 2015-01-27 HK HK15100892.2A patent/HK1200342A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2788001B1 (en) | 2015-12-02 |
IL232944A0 (en) | 2014-07-31 |
US20130167838A1 (en) | 2013-07-04 |
WO2013083569A1 (en) | 2013-06-13 |
GB201121812D0 (en) | 2012-02-01 |
AR089101A1 (es) | 2014-07-30 |
CA2856043C (en) | 2017-01-17 |
DK2788001T3 (en) | 2016-02-01 |
PL2788001T3 (pl) | 2016-04-29 |
HUE026612T2 (hu) | 2016-06-28 |
TW201330879A (zh) | 2013-08-01 |
ES2560029T3 (es) | 2016-02-17 |
CA2856043A1 (en) | 2013-06-13 |
EP2788001A1 (en) | 2014-10-15 |
HK1200342A1 (zh) | 2015-08-07 |
MX2014006769A (es) | 2015-01-16 |
TWI468193B (zh) | 2015-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
CR20130556A (es) | FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7 | |
CR20130663A (es) | Composiciones farmcéuticas inhalables | |
ECSP15013227A (es) | Formulaciones acuosas estables de adalimumab | |
CR20150326A (es) | Inhibidores de autotaxina | |
CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
BR112014030714A2 (pt) | composto de lipídeo ionizável , composições , carreador de fármaco , formulação farmacêutica e método de entrega de um fármaco | |
CR20140321A (es) | Sistema de administracion transdermica que contiene buprenofina | |
UY34698A (es) | Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
EA201600495A1 (ru) | Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение | |
CL2014000995A1 (es) | Composicion de prodroga que comprende un conjugado de hidromorfona y un acido arilcarboxilico; un método para tratar un paciente que comprende la administracion de la composicion. | |
BR112013012587A2 (pt) | composição farmacêutica para administração nasal | |
IT1402018B1 (it) | Formulazioni per il trattamento delle affezioni delle prime vie respiratorie. | |
GT201400090A (es) | 2-tiopirimidinonas | |
BR112013016241A2 (pt) | composto, e, método para fabricar um composto | |
BRPI1007732A2 (pt) | aparelho para administração de medicamentos para a administração de um aerossol incluindo um medicamento para um paciente, kit para a administração de um aerossol incluindo um medicamento para um paciente e método de administração de um aerossol incluindo um medicamento para um paciente | |
CL2017000394A1 (es) | Composición que contiene cineol para la administración nasal | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
CL2014003055A1 (es) | Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica. | |
MY193312A (en) | Topical formulation for promoting wound healing | |
CO2017007316A2 (es) | Formulación farmacéutica | |
ECSP12011618A (es) | Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol | |
UY34931A (es) | ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201020 |